Clinical trials: Lung Fibrosis Interstitial
Idiopathic Pulmonary Fibrosis
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05537025
- Testing
- ARO-MMP7 Inhalation Solution
- Where
- 19 sites in Denmark, Italy and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Idiopathic Pulmonary Fibrosis
D2212C00002 J-Phase II Study
The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT02036580
- Testing
- tralokinumab cohort 1, tralokinumab cohort 2
- Where
- 5 sites in Japan
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Idiopathic Pulmonary Fibrosis
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment…
- Trial name
- NCT02788474
- Testing
- nintedanib
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 347 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).
- Trial name
- RISE-IIP (NCT02138825)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 93 sites in United States, Argentina and 19 more
- Volunteers
- 147 people
- Sponsor
- Bayer
Idiopathic Pulmonary Fibrosis
The Effect of N115 on Coughing in IPF Patients
The purpose of this clinical trial is to administer a sodium pyruvate nasal spray that eliminates nasal oxidative stresses, caused by oxygen radicals, and demonstrate the efficacy of sodium pyruvate to reduce coughing and…
- Trial name
- NCT06037408
- Testing
- 20mM sodium pyruvate nasal spray
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cellular Sciences, inc.
Idiopathic Pulmonary Fibrosis
Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain
The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from January 2016 in Spanish…
- Trial name
- NCT03281200
- Testing
- L - Antineoplastic and immunomodulating agents, L01 - Antineoplastic agents, L01X - Other antineoplastic agents
- Where
- Spain
- Volunteers
- 172 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis (IPF)
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.
- Trial name
- NCT03832946
- Testing
- GB0139
- Where
- 128 sites in United States, Australia and 13 more
- Volunteers
- 172 people
- Sponsor
- Galecto Biotech AB
Pulmonary Fibrosis
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of…
- Trial name
- NCT04308681
- Testing
- BMS-986278
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 403 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause that results in scarring of the lungs. Cough is reported by 85% of patients with IPF and can be a distressing symptom with significant physical, social and…
- Trial name
- PAciFy Cough (NCT04429516)
- Testing
- Morphine Sulfate
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)
The primary objective of this study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in participants with idiopathic pulmonary fibrosis (IPF) who had previously participated in Gilead clinical trial…
- Trial name
- ATLAS (NCT01759511)
- Testing
- Simtuzumab
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Gilead Sciences
Idiopathic Pulmonary Fibrosis
BUILD 3: Bosentan Use in Interstitial Lung Disease
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study.
- Trial name
- BUILD 3 (NCT00391443)
- Testing
- Bosentan
- Volunteers
- 616 people
- Sponsor
- Actelion
Idiopathic Pulmonary Fibrosis
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).
Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it.
- Trial name
- NCT05513950
- Testing
- CHF10067 starting dose -- 1000mg (Cohort A), CHF10067 intermediate dose -- 2000mg (Cohort B), CHF10067 high dose -- 3000mg (Cohort C)
- Where
- 9 sites in North Macedonia, Ukraine and 1 more
- Volunteers
- 52 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
Treatment of IPF With Laparoscopic Anti-Reflux Surgery
This study will test the hypothesis that treatment with laparoscopic anti-reflux surgery in subjects with idiopathic pulmonary fibrosis (IPF) and abnormal gastroesophageal reflux (GER) will slow the decline of forced vital…
- Trial name
- WRAP-IPF (NCT01982968)
- Testing
- Surgery
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of California, San Francisco
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Families-At-risk for Interstitial Lung Disease Study
The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia.
- Trial name
- FAR-ILD (NCT03641742)
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Columbia University
Idiopathic Pulmonary Fibrosis
Genentech Xenon MRI Idiopathic Pulmonary Fibrosis
The purpose of this study is being done to determine whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic…
- Trial name
- NCT04071769
- Testing
- Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Duke University
Pulmonary Fibrosis
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
Primary objective of this study is to investigate the long-term tolerability and safety profile of BIBF 1120 on top of pirfenidone treatment in patients with Idiopathic Pulmonary Fibrosis who have completed a prior clinical trial…
- Trial name
- NCT01417156
- Testing
- Nintedanib, Pirfenidoneone
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
The primary objective of this study is to evaluate the efficacy of BG00011 compared with placebo in participants with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- SPIRIT (NCT03573505)
- Testing
- BG00011
- Where
- 90 sites in United States, Argentina and 15 more
- Volunteers
- 109 people
- Sponsor
- Biogen
Idiopathic Pulmonary Fibrosis
OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
Descriptive prospective non-interventional multicenter study based on newly collected data of Idiopathic Pulmonary Fibrosis patients followed-up for one year in secondary care settings (Pulmonology Services)
- Trial name
- NCT03386994
- Where
- 31 sites in Spain
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis…
- Trial name
- STARSCAPE (NCT04552899)
- Testing
- PRM-151 (Zinpentraxin Alfa)
- Where
- 360 sites in United States, Argentina and 33 more
- Volunteers
- 665 people
- Sponsor
- Hoffmann-La Roche
Lung Diseases, Interstitial
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old.
- Trial name
- NCT05065190
- Testing
- Nintedanib
- Where
- 16 sites in China
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim